adg116
adg116: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: Adagene Inc. (ADAG)
Development Pipeline (1)
| Company | Phase |
|---|---|
| Adagene Inc. (ADAG) | Phase 1 |
Clinical Trials (1)
A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG116, ADG116 Combined With Toripalimab (Anti-PD-1 Antibody), ADG116 Combined With ADG106 (Anti-CD137 Antibody) in Patients With Advanced/Metastatic Solid Tumors
Frequently asked questions
Who is developing adg116?
adg116 is being developed by Adagene Inc..
How many clinical trials involve adg116?
BioSniper tracks 1 clinical trial involving adg116.
Analyze Adagene Inc. & adg116 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company